Three Million Wegovy Scripts and a $50 Cap: Novo Nordisk’s Volume Victory Comes With a Margin Hangover

Wegovy becomes fastest-selling obesity drug with 3M scripts in 5 months, but Novo Nordisk shares fall 22% YTD amid Medicare pricing caps and competitive pressures.

Novo Nordisk’s oral Wegovy has become the fastest-selling obesity drug in US history, with three million prescriptions filled in just five months. But the stock market is not cheering. The Danish pharma giant’s shares have shed roughly a fifth of their value since January, as investors fixate on the pricing headwinds and competitive threats that could erode the very profitability those scripts are supposed to generate.

A pack of the weekly pill now leaves a US pharmacy counter every five seconds. More than 80% of patients had never taken a GLP-1 medicine before, signaling genuine market expansion rather than brand switching. The first million prescriptions took twelve weeks from the January launch; the second and third million arrived in just ten weeks combined. The commercial trajectory is unmistakable.

Yet the stock closed at around $41 in New York on Tuesday, down roughly 22% year to date and some 48% below its 52-week high in euro terms (€36.41). The disconnect between operational momentum and share price has rarely been so stark.

Medicare’s Pricing Leapfrog

Starting 1 July 2026, a new federal program will cap out-of-pocket costs for GLP-1 drugs at $50 per month for eligible seniors. The so-called Medicare GLP-1 Bridge covers Wegovy, rival Eli Lilly’s Foundayo, and competing products alike. For Novo Nordisk, the policy is a double-edged sword: it expands the addressable patient pool dramatically, but it also flattens the pricing curve. Barclays analyst James Gordon has flagged the “many moving parts” in the model, particularly whether patients will trade up to higher-dose, higher-margin versions of the drug or stick with the baseline.

The volume-versus-margin tradeoff is already showing up in management’s revised guidance. Novo Nordisk now expects adjusted revenue and profit to decline by 4% to 12% this year, an improvement from the earlier 5% to 13% range. The narrowing still represents a contraction, and the second-quarter results due within weeks will be the first real test of whether the script explosion can translate into proportionate top-line growth.

Pipeline Breadth and AI Acceleration

Beneath the surface, Novo Nordisk is waging a two-front strategy: defending its existing blockbuster while expanding the scientific narrative. At the ADA Scientific Sessions 2026, CEO Mike Doustdar positioned semaglutide not merely as a weight-loss drug but as a molecule that can reduce the “biological age” of the heart and kidneys. The company has even begun exploring aesthetic applications such as skin care and hair loss.

The REIMAGINE program delivered fresh Phase?3 ammunition. In REIMAGINE?2, the combination therapy CagriSema (cagrilintide plus semaglutide) outperformed standard of care on HbA1c and body weight among 2,713 participants. REIMAGINE?3 showed that CagriSema as an add?on to insulin produced weight loss of up to 12%.

To accelerate future development, Novo Nordisk struck a collaboration with OpenAI in April, deploying artificial intelligence to automate data collection and simulate virtual clinical trials. The goal is to cut development timelines and make faster go/no-go decisions—a logical step given the intensifying competition.

A Three-Way Race for Oral GLP-1 Dominance

The competitive landscape is thickening fast. Eli Lilly launched its own daily oral GLP-1, Foundayo, in April?2026. AstraZeneca, after positive Phase?2b data, is moving an oral candidate into Phase?3. Novo Nordisk’s oral Wegovy holds a first-mover advantage in the tablet segment, but the window of exclusivity is narrowing.

The company is not sitting still. A 15?billion Danish kroner ($2.2?billion) share buyback programme is underway. And later this year, the oral Wegovy will roll out internationally, starting with the United Arab Emirates in the second half of 2026.

For now, Novo Nordisk finds itself in a peculiar bind: the strongest prescription growth in its history, a pipeline rich with data, and a stock that refuses to rally. The summer months will determine whether the next catalyst—Q2 revenue, Medicare’s impact, or a potential CagriSema approval—can finally close the gap between commercial reality and market sentiment.